Answers are grounded in this paper and cite their sources.
An FDA program established in the 1990s made it easier for manufacturers to get devices for rare diseases into use. Thomas J Hwang and colleagues examine how the program has been used and what can be learnt for US and European device regulation
No takes yet. Share an insight, caveat, or question.
Hwang et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: